![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, March 25, 2004 10:21:29 PM
http://www.Eudragene.com
Here's an excerpt:
EUDRAGENE
European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions
This project is funded with support from the European Union from 2003-06 (Project number: QLRT-2001-02757)
Coordinator: Paul McKeigue <paul.mckeigue@ucd.ie> Professor of Metabolic and Genetic Epidemiology, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, UK
Tel: +44 20 7927 2633
Objectives
The specific objectives of this study is to establish a collection of DNA samples as a resource for studying genes which influence serious or adverse drug reactions (ADRs). Identifying genes that influence susceptibility to adverse reactions will advance understanding of the basis of adverse drug reactions and may also lead to the development of tests that can predict individual susceptibility to adverse reactions, with obvious benefits to human health.
At least 500 cases of each ADR will be collected, together with an equal number of healthy volunteers. The co-ordinating centre will manage the database, and will make samples freely available to academic and industry-based researchers throughout Europe. The collection will be extended to include more ADRs after the first 1-2 years, based on problems of current concern.....
Later,
W2P
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM